PRS17 COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS WITH PALIVIZUMAB FROM THE PERSPECTIVE OF A SOUTHERN US MEDICAID AGENCY
Oct 1, 2009, 00:00 AM
10.1016/S1098-3015(10)74479-X
https://www.valueinhealthjournal.com/article/S1098-3015(10)74479-X/fulltext
Section Title :
Section Order :
402
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74479-X&doi=10.1016/S1098-3015(10)74479-X